Company Overview
XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment provides traveler's spa services, including massage, and nail and skin care services, as well as spa and travel products. The XpresTest segment offers COVID-19 and other medical testing to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. customs and border protection agents; aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program; and various services and support, including technical support services and advanced services. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. It offers its services through stores and kiosks, as well as online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
Why Investors Should Care
Net profit has compounded at 16.1% per year over the last five years.
Recent Developments
- Dec 2025 Revenue of $29.21M (-13.8% YoY); net profit $-16.99M.
- Trailing 12 Months Year-on-year growth — revenue -5.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -19.5%, profit CAGR 16.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -19.47% |
| 1 Year: | -5.50% |
Compounded Profit Growth
| 5 Years: | 16.09% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -2.97% |
| 6 Months: | +237.93% |
| 3 Months: | -16.95% |
| 1 Month: | -7.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)40.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 16.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -19.5% CAGR over 5 years.
- Trading 42.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XWEL XWELL, Inc. | 0.98 | -0.18 | $8.28M | 0.00% | - | - | -19.47% | 16.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 7.02M | 7.69M | 7.34M | 7.15M | 6.64M |
| Cost of Revenue | - | 5.70M | 5.91M | 5.85M | 4.23M | 4.29M |
| Gross Profit | - | 1.32M | 1.77M | 1.49M | 2.92M | 2.35M |
| Operating Expenses | - | 4.48M | 4.47M | 1.77M | 6.14M | 7.77M |
| Operating Income | - | -3.16M | -2.69M | -282.00K | -3.22M | -5.41M |
| EBITDA | - | -4.15M | -2.26M | 166.00K | -9.32M | -10.69M |
| Interest Expense | - | 30.00K | - | - | - | 68.00K |
| Pretax Income | - | -4.59M | -2.02M | -209.00K | -9.26M | -11.01M |
| Tax Provision | - | 0 | 34.00K | 2.00K | -7.00K | 0 |
| Net Income | - | -4.72M | -2.27M | -724.00K | -9.28M | -11.20M |
| Diluted EPS | - | -1.00 | -0.56 | -0.26 | - | -1.51 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 55.94M | 30.11M | 33.90M | 29.21M |
| Cost of Revenue | - | 43.89M | 26.43M | 24.98M | 21.70M |
| Gross Profit | - | 12.05M | 3.68M | 8.92M | 7.51M |
| Operating Expenses | - | 36.60M | 22.98M | 21.02M | 16.86M |
| Operating Income | - | -24.55M | -19.30M | -12.10M | -9.36M |
| EBITDA | - | -17.28M | -15.75M | -13.99M | -14.16M |
| Interest Expense | - | - | - | 179.00K | 134.00K |
| Pretax Income | - | -32.57M | -27.99M | -16.44M | -16.08M |
| Tax Provision | - | 55.00K | 35.00K | 49.00K | 29.00K |
| Net Income | - | -32.84M | -27.74M | -16.85M | -16.99M |
| Diluted EPS | - | -7.01 | -6.64 | -3.66 | -5.08 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 70.43M | 38.99M | 25.35M | 11.22M |
| Current Assets | - | 47.33M | 26.57M | 15.34M | 5.91M |
| Cash & Equivalents | - | 19.04M | 8.44M | 4.55M | 2.62M |
| Inventory | - | 1.16M | 900.00K | 501.00K | 509.00K |
| Receivables | - | 2.86M | 1.67M | 1.79M | 1.56M |
| Total Liabilities | - | 22.48M | 18.02M | 17.61M | 23.80M |
| Current Liabilities | - | 10.96M | 9.33M | 9.22M | 12.89M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 14.11M | 11.09M | 10.77M | 12.49M |
| Total Equity | - | 39.93M | 13.00M | -788.00K | -22.04M |
| Shares Outstanding | - | 4.16M | 4.18M | 5.26M | 6.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -24.19M | -16.07M | -11.01M | -8.71M |
| Investing Cash Flow | - | -34.84M | 5.65M | 5.89M | 4.33M |
| Financing Cash Flow | - | -27.38M | 8.00K | 1.36M | 1.94M |
| Capital Expenditure | - | -6.84M | -2.37M | -1.79M | -2.96M |
| Free Cash Flow | - | -31.02M | -18.45M | -12.80M | -11.68M |
| Net Change in Cash | - | -86.41M | -10.42M | -3.75M | -2.44M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 21.5% | 12.2% | 26.3% | 25.7% |
| Operating Margin % | - | -43.9% | -64.1% | -35.7% | -32.0% |
| Net Margin % | - | -58.7% | -92.1% | -49.7% | -58.2% |
| ROE % | - | -82.2% | -213.4% | 2,138.7% | 77.1% |
| ROCE % | - | -41.3% | -65.0% | -75.0% | 558.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 0.97% | 82.16K | $80.52K |
| 2 | Blackrock Inc. | 0.97% | 81.99K | $80.35K |
| 3 | Geode Capital Management, LLC | 0.80% | 67.52K | $66.17K |
| 4 | Vanguard Capital Management LLC | 0.61% | 51.31K | $50.28K |
| 5 | Vanguard Fiduciary Trust Co | 0.28% | 23.38K | $22.91K |
| 6 | Morgan Stanley | 0.26% | 21.89K | $21.45K |
| 7 | State Street Corporation | 0.19% | 16.14K | $15.82K |
| 8 | UBS Group AG | 0.14% | 12.09K | $11.85K |
| 9 | Integrated Wealth Concepts LLC | 0.12% | 10.35K | $10.14K |
| 10 | Tower Research Capital LLC (TRC) | 0.05% | 4.54K | $4.45K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XWEL
XWEL — Frequently Asked Questions
What is the current share price of XWELL, Inc. (XWEL)?
As of 2026-08-02 19:16 PDT, XWELL, Inc. (XWEL) trades at $0.98 on NasdaqCM. Its 52-week range is $0.29 to $1.70.
What is the market capitalisation of XWEL?
XWELL, Inc. (XWEL) has a market capitalisation of $8.28M on NasdaqCM.
What is the P/E ratio of XWEL?
XWEL trades at a trailing price-to-earnings (P/E) ratio of -0.18. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is -0.89.
Is XWEL a good stock to buy?
This page provides a data-driven analysis of XWELL, Inc. (XWEL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.